Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

Leukemia

Volumn 20, Issue 10, 2006, Pages 1819-1828

  Loskog, A ^a,b   Giandomenico, V ^b   Rossig, C ^c   Pule, M ^a   Dotti, G ^a   Brenner, M K ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; B LYMPHOCYTE; CELL ACTIVITY; CELL PROLIFERATION; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DONOR; ENZYME INDUCTION; GENETIC TRANSDUCTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LYMPHOCYTOTOXICITY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION;

EID: 33750061330     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404366     Document Type: Article

References (33)

1. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 2004; 10: 5-18.
2. Mekala DJ, Alli RS, Geiger TL. IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Proc Nat Acad Sci 2005; 102: 11817-11822.
3. Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy 2003; 5: 211-226.
4. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10: 801-805.
5. D'Orazio TJ, Niederkorn JY. A novel role for TGF-β and IL-10 in the induction of immune privilege. J Immunol 1998; 160: 2089-2098.
6. Beacher-Allan C, Viglietta V, Hafler D. Human CD4+CD25+ regulatory T-cells. Sem Immunol 2004; 16: 89-97.
7. Coffer PJ, Burgering BMT. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 2004; 4: 889-899.
8. Fehérvari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004; 114: 1209-1217.
9. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A et al. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 2005; 11: 6916-6923.
10. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917-2924.
11. Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A et al. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 2004; 33: 83-89.
12. Cooper LJN, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A et al. T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101: 1637-1644.
13. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-2025.
14. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Chen D et al. TGF-b induces Foxp3+ T-regulatory cells from CD4+CD25- precursors. Am J Transplant 2004; 4: 1614-1627.
15. Nicholson IC, Lenton KA, Little DJ, Decorso T, Lee FT, Scott AM et al. Construction and characterization of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 1997; 34: 1157-1165.
16. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Pro Natl Acad Sci USA 1993; 90: 720-724.
17. Weissman AM, Hou D, Orloff DG, Modi WS, Seuanex H, O'Brien SJ et al. Molecular cloning and chromosomal localization of the human T-cell receptor zeta chain: Distinction from the molecular CD3 complex. Proc Natl Acad Sci USA 1988; 85: 9709-9713.
18. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733-6737.
19. Cosset F-L, Takeuchi Y, Battini J-L, Weiss RA, Collins MKL. Hightiter packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
20. Kane LP, Lin J, Weiss A. It's all Rel-ative: NFκB and CD28 costimulation of T-cell activation. Trends Immunol 2002; 23: 413-420.
21. Chambers CA. The expanding world of co-stimulation: The two-signal model revisited. Trends Immunol 2001; 22: 217-223.
22. Parry RV, Whittaker GC, Sims M, Edmead CE, Welham MJ, Ward SG. Ligation of CD28 stimulates the formation of a multimeric signaling complex involving Grb-2-associated binder 2 (Gab2), src homology phosphatase-2, and phosphatidylinositol 3-kinase: Evidence that negative regulation of CD28 signaling requires the Gab2 pleckstrin homology domain. J Immunol 2006; 176: 594-602.
23. Appleman LJ, Tzachanis D, Grader-Beck T, van Puijenbroek AA, Boussiotis VA. Helper T cell anergy: From biochemistry to cancer pathophysiology and therapeutics. J Mol Med 2001; 78: 673-683.
24. Mesa C, Fernandez LE. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 2004; 82: 644-650.
25. Thomas RM, Gao L, Wells AD. Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J Immunol 2005; 174: 4639-4646.
26. Slavik JM, Hutchcroft JE, Bierer BE. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res 1999; 19: 1-24.
27. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002; 20: 70-75.
28. Haynes NM, Trapani JA, Teng MWL, Jackson JT, Cerruti L, Jane SM et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002; 169: 5780-5786.
29. Teng MWL, Kershaw MH, Moeller M, Smyth MJ, Darcy PK. Immunotherapy of cancer using systemically delivered genemodified human T-lymphocytes. Human Gene Ther 2004; 15: 699-708.
30. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 2005; 105: 3087-3093.
31. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004; 114: 1209-1217.
32. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22: 929-979.
33. Letterio JJ. TGF-beta signaling in T cells: Roles in lymphoid and epithelial neoplasia. Oncogene 2005; 24: 5701-5712.